:

BOARD RAISES $20M FOR INTERACTIVE TABLETOP DEVICE

AI DESK1 MIN READ
TUE, JUN 2, 2026

■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE

Board, a New York startup that makes a 24-inch touchscreen device merging board games with video game interactivity, has closed a $20M Series A funding round. The company reports it has already sold tens of thousands of units.

Board's device targets the "together tech" category—hardware designed to keep people physically gathered rather than isolated by screens. The 24-inch touchscreen enables digital board games with real-time interactivity impossible on traditional tables, while maintaining the social dynamics of in-person play. The three-year-old startup's Series A demonstrates investor confidence in the hybrid gaming category. Strong early sales—in the tens of thousands—suggest meaningful consumer demand for devices that blend analog and digital gaming experiences. Board competes in a niche market where tabletop entertainment meets digital innovation. The funding provides capital to scale manufacturing, expand its game library, and develop new features for the touchscreen platform. Details on the funding round's lead investors and Board's valuation were not disclosed.

■ SOURCES

Techmeme

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE STARTUPS DESK

Colorado-based biotech startup Enveda, which uses AI to discover new drugs from natural sources, secured $311 million in Series E funding at a $2 billion valuation—double its valuation from a year ago.

4H AGOAI Desk

Modal Labs and Baseten, two platforms enabling businesses to run AI models, are in advanced funding talks that would significantly boost their valuations. The rounds reflect growing investor appetite for AI infrastructure services.

6H AGOAI Desk

Ema, an AI agent platform automating corporate processes in HR, IT, and finance, secured $77 million in Series B funding led by Creaegis. The round brings the startup's total funding to $140 million.

8H AGOAI Desk

Enveda Therapeutics raised $311 million in funding, bringing the AI biotech company's valuation to $2 billion. The capital will accelerate clinical trials for drugs derived from natural compounds.

9H AGOAI Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.